Abstract: Some embodiments of the invention provide a mouthpiece for use with an electronic analyzer for breath analyte detection in an individual. The mouthpiece includes a biosensor and a hydration system. The biosensor includes a chemically active area where a chemical reaction takes place and the hydration system delivers a liquid to the chemically active area of the biosensor to at least one of enhance, enable, and facilitate the chemical reaction. The mouthpiece further includes hardware to transmit breath analyte data.

Abstract: Some embodiments of the invention provide a mouthpiece for use with an electronic analyzer for breath analyte detection in an individual. The mouthpiece includes a biosensor and a hydration system. The biosensor includes a chemically active area where a chemical reaction takes place and the hydration system delivers a liquid to the chemically active area of the biosensor to at least one of enhance, enable, and facilitate the chemical reaction. The mouthpiece further includes hardware to transmit breath analyte data.

Abstract: Some embodiments of the invention provide a mouthpiece for use with an electronic analyzer for breath analyte detection in an individual. The mouthpiece includes a biosensor and a hydration system. The biosensor includes a chemically active area where a chemical reaction takes place and the hydration system delivers a liquid to the chemically active area of the biosensor to at least one of enhance, enable, and facilitate the chemical reaction. The mouthpiece further includes hardware to transmit breath analyte data.

Abstract: Described are enzyme systems specific for acetone and methods of using these enzyme systems to detect acetone in biological or environmental samples. Biosensors containing these enzyme systems are disclosed, in which detection of acetone may be achieved by linking electrochemical, photometric, or other detection means to one or more acetone-specific enzyme reactions or pathways. Methods of using such acetone-specific biosensors include subject management of weight loss, disease detection, and bioavailability monitoring of therapeutics.

Abstract: A tablet, pill or capsule containing a material which produces sound waves when the tablet, pill or capsule is exposed to the gastrointestinal system. A two step method for oral drug compliance monitoring. The first step is to ingest a tablet, pill or capsule containing a material which produces sound waves when the tablet, pill or capsule is exposed to the gastrointestinal system of a person. The second step is to detect the sound waves produced when the tablet, pill or capsule is exposed to the gastrointestinal system to confirm that the person has ingested the tablet, pill or capsule.

Abstract: Some embodiments of the invention provide a mouthpiece for use with an electronic analyzer for breath analyte detection in an individual. The mouthpiece includes a biosensor and a hydration system. The biosensor includes a chemically active area where a chemical reaction takes place and the hydration system delivers a liquid to the chemically active area of the biosensor to at least one of enhance, enable, and facilitate the chemical reaction. The mouthpiece further includes hardware to transmit breath analyte data.

Abstract: A device useful for oral drug delivery device consisting of: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the capsule, tablet or pill, the RFID tag comprising an antenna; (c) an object selected from the group consisting of a magnet, a ferromagnetic object, a ferrite object and an electromagnetic shielding object positioned within, over or adjacent the antenna of the RFID tag to alter the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the capsule, tablet or pill has dispersed in the gastrointestinal system, the object separates from the RFID tag so that the response of the RFID tag is sufficiently detectable to determine that t

Abstract: The subject invention provides a hand-held medical apparatus (10) for detecting a predetermined component of user breath and producing a breath-component signal over a measurement time. Such breath-component signal may be correlated to a user fat metabolism indicator.

Abstract: The subject invention provides a hand-held medical apparatus (10) for detecting a predetermined component of user breath and producing a breath-component signal over a measurement time. Such breath-component signal may be correlated to a user fat metabolism indicator.

Abstract: A medical breath component analyzer which maintains a data-base profile of a patient over time. The apparatus may be used chronically by a patient so that a baseline status for that patient may be determined. Acute variations from the baseline are identified as clinically significant. The acquired data can be reported to the patient using the device at home and transmitted electronically to a physician or health care provider. The method and apparatus helps a patient modify health related behaviors, particularly weight loss for diabetic patients. A breath component and information on the psychological or emotional state of the patient are correlated, and information is provided to the patient based on the correlation between the breath component and the patient's emotional state. Other physiologic parameter may also be measured, such as a blood component, temperature, cardiovascular condition or pulse rate, a urine component, a physical activity sensor, weight, or body fat composition sensor.

Abstract: The invention is a high molecular weight polyether polyol prepared by the reaction of one or more compounds having one or more active hydrogen compounds with one or more alkylene oxides in the presence of a catalyst comprising calcium having counterions of carbonate and a C6-10 alkanoate in a solvent or dispersant which does not contain active hydrogen atoms. The polyether polyol prepared preferably has an equivalent weight of from about 1000 to about 20,000, a polydispersity of 1.3 or less and a residual catalyst level of from about 0 to about 2000 parts per million (ppm). In another embodiment the invention is a process for preparing such high molecular weight polyether polyols. The process comprises first, contacting one or more compounds having one or more active hydrogen atoms with one or more alkylene oxides in the presence of a catalyst. The catalyst comprises calcium having counterions of carbonate and a C6-10 alkanoate in a solvent, wherein the solvent does not contain active hydrogen atoms.

Abstract: The invention is a high molecular weight polyether polyol prepared by the reaction of one or more compounds having one or more active hydrogen compounds with one or more alkylene oxides in the presence of a catalyst comprising calcium having counterions of carbonate and a C6-10 alkanoate in a solvent or dispersant which does not contain active hydrogen atoms. The polyether polyol prepared preferably has an equivalent weight of from about 1000 to about 20,000, a polydispersity of 1.3 or less and a residual catalyst level of from about 0 to about 2000 parts per million (ppm). In another embodiment the invention is a process for preparing such high molecular weight polyether polyols. The process comprises first, contacting one or more compounds having one or more active hydrogen atoms with one or more alkylene oxides in the presence of a catalyst. The catalyst comprises calcium having counterions of carbonate and a C6-10 alkanoate in a solvent, wherein the solvent does not contain active hydrogen atoms.

Abstract: The invention is a high molecular weight polyether polyol prepared by the reaction of one or more compounds having one or more active hydrogen compounds with one or more alkylene oxides in the presence of a catalyst comprising calcium having counterions of carbonate and a C6-10 alkanoate in a solvent or dispersant which does not contain active hydrogen atoms. The polyether polyol prepared preferably has an equivalent weight of from about 1000 to about 20,000, a polydispersity of 1.3 or less and a residual catalyst level of from about 0 to about 2000 parts per million (ppm). In another embodiment the invention is a process for preparing such high molecular weight polyether polyols. The process comprises first, contacting one or more compounds having one or more active hydrogen atoms with one or more alkylene oxides in the presence of a catalyst. The catalyst comprises calcium having counterions of carbonate and a C6-10 alkanoate in a solvent, wherein the solvent does not contain active hydrogen atoms.

Abstract: A medical breath component analyzer which maintains a data-base profile of a patient over time. The apparatus may be used chronically by a patient so that a baseline status for that patient may be determined. Acute variations from the baseline are identified as clinically significant. The acquired data can be reported to the patient using the device at home and transmitted electronically to a physician or health care provider. The method and apparatus helps a patient modify health related behaviors, particularly weight loss for diabetic patients. A breath component and information on the psychological or emotional state of the patient are correlated, and information is provided to the patient based on the correlation between the breath component and the patient's emotional state. Other physiologic parameter may also be measured, such as a blood component, temperature, cardiovascular condition or pulse rate, a urine component, a physical activity sensor, weight, or body fat composition sensor.

Abstract: A medical breath component analyzer which maintains a data-base profile of a patient over time. The apparatus may be used chronically by a patient so that a baseline status for that patient may be determined. Acute variations from the baseline are identified as clinically significant. The acquired data can be reported to the patient using the device at home and transmitted electronically to a physician or health care provider. Multiple tests may be provided, ranging from quantitative tests to qualitative tests to quantitative approximations using qualitative devices. A set of tests is selected for a particular patient, and may be customized to the patient's condition. One of the tests may include passing multiple laser beams of differing wavelengths through a breath sample and using pattern recognition to correlate from spectral analysis of all the laser beams.

Abstract: The invention is a high molecular weight polyether polyol prepared by the reaction of one or more compounds having one or more active hydrogen compounds with one or more alkylene oxides in the presence of a catalyst comprising calcium having counterions of carbonate and a C6-10 alkanoate in a solvent or dispersant which does not contain active hydrogen atoms. The polyether polyol prepared preferably has an equivalent weight of from about 1000 to about 20,000, a polydispersity of about 1.3 or less and a residual catalyst level of from about 0 to about 2000 parts per million (ppm).